MINDDS will come to the end of its COST Action status and funding on May 6th 2022. We all would like to thank the COST Association for supporting us over the last four and a half years.

The general feeling of the network however is that research in this area is accelerating, and we may be on the edge of major breakthrough in NDD research. We believe that there is still a significant role of MINDDS in supporting this next research phase and developing a dialogue with our patient community.

We have therefore launched our Future Project to identify our next activities and consider how best to coordinate.

If you wish to participate in shaping MINDDS’ future, please contact Prof Adrian J Harwood on or follow us at


Understanding rare neurodevelopmental disorders (NDD) has the potential drive major new therapies for the common NDD of schizophrenia and Autism Spectrum Disorder (ASD).